ID: h-6c347bffd7
Hypothesis
TREM2 Agonism to Promote Neuroprotective Microglial Phenotype in Alzheimer's Disease
Enhancing TREM2 signaling shifts microglia toward a neuroprotective state with improved lipid metabolism, enhanced phagocytosis of amyloid plaques, and reduced neurotoxicity.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 4 support✗ 3 oppose
✓ All Quality Gates Passed
🧪 Overview
Enhancing TREM2 signaling shifts microglia toward a neuroprotective state with improved lipid metabolism, enhanced phagocytosis of amyloid plaques, and reduced neurotoxicity. TREM2 R47H variants confer ~3-fold AD risk. Agonistic antibodies developed by Alector/AbbVie showed target engagement but AL002 Phase 2 failed to meet primary clinical endpoints.
🧬 Mechanism
No curated mechanism pathway recorded for this hypothesis.
⚖️ Evidence
⚖️ Evidence Matrix4 supports3 contradicts
Supports
TREM2 agonistic antibodies promote microglial plaque compaction and reduce neuritic dystrophy
Contradicts
AL002 Phase 2 failed to slow CDR-SB progression or improve secondary clinical endpoints
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — TREM2
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for TREM2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↘
Falling
7d Momentum
▼ 1.1%
Volatility
Low
0.0021
Events (7d)
3
Price History
▼13.4%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF AD patients (n≥120, aged 55-85, amyloid-positive by PET, including ≥40 with TREM2 R47H/R47H or R47H/wt genotype) receive a TREM2 agonistic antibody (AL002 or bioequivalent) at 10mg/kg IV every 4 we | ≥50% increase in CSF sTREM2; ≥15% decrease in plasma NfL in TREM2 R47H carriers | — no observation — | pending | 0.45 |
| IF a selective TREM2 agonist (e.g., AL002 or a surrogate compound) is administered to 5xFAD mice (n≥15/group) for 12 weeks starting at 4 months of age, THEN hippocampal amyloid plaque burden will decr | ≥30% reduction in amyloid plaque density in hippocampus; ≥2-fold increase in microglial TREM2 pathway activation markers | — no observation — | pending | 0.55 |
🔮 Falsifiable Predictions (2)
pendingconf 55%
IF a selective TREM2 agonist (e.g., AL002 or a surrogate compound) is administered to 5xFAD mice (n≥15/group) for 12 weeks starting at 4 months of age, THEN hippocampal amyloid plaque burden will decrease by ≥30% (measured by Thioflavin-S or 6E10 immunostaining) and microglial TREM2 downstream signa
Predicted outcome: ≥30% reduction in amyloid plaque density in hippocampus; ≥2-fold increase in microglial TREM2 pathway activation markers
Falsification: No significant reduction in amyloid plaque burden (p>0.05) OR no increase in TREM2 signaling markers below stated thresholds
pendingconf 45%
IF AD patients (n≥120, aged 55-85, amyloid-positive by PET, including ≥40 with TREM2 R47H/R47H or R47H/wt genotype) receive a TREM2 agonistic antibody (AL002 or bioequivalent) at 10mg/kg IV every 4 weeks for 48 weeks, THEN CSF soluble TREM2 (sTREM2) will increase by ≥50% from baseline (Week 0) AND p
Predicted outcome: ≥50% increase in CSF sTREM2; ≥15% decrease in plasma NfL in TREM2 R47H carriers
Falsification: No significant increase in CSF sTREM2 (fold-change <1.5) OR no reduction/decrease in plasma NfL in R47H carriers at Week 48
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.